Electrocardiographic predictors of successful resynchronization of left bundle branch block by His bundle pacing

Background His bundle pacing (HBP) is an alternative to biventricular pacing (BVP) for delivering cardiac resynchronization therapy (CRT) in patients with heart failure and left bundle branch block (LBBB). It is not known whether ventricular activation times and patterns achieved by HBP are equivale...

Full description

Saved in:
Bibliographic Details
Published inJournal of cardiovascular electrophysiology Vol. 32; no. 2; pp. 428 - 438
Main Authors Arnold, Ahran D., Shun‐Shin, Matthew J., Keene, Daniel, Howard, James P., Chow, Ji‐Jian, Lim, Elaine, Lampridou, Smaragda, Miyazawa, Alejandra A., Muthumala, Amal, Tanner, Mark, Qureshi, Norman A., Lefroy, David C., Koa‐Wing, Michael, Linton, Nick W. F., Boon Lim, Phang, Peters, Nicholas S., Kanagaratnam, Prapa, Auricchio, Angelo, Francis, Darrel P., Whinnett, Zachary I.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.02.2021
John Wiley and Sons Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background His bundle pacing (HBP) is an alternative to biventricular pacing (BVP) for delivering cardiac resynchronization therapy (CRT) in patients with heart failure and left bundle branch block (LBBB). It is not known whether ventricular activation times and patterns achieved by HBP are equivalent to intact conduction systems and not all patients with LBBB are resynchronized by HBP. Objective To compare activation times and patterns of His‐CRT with BVP‐CRT, LBBB and intact conduction systems. Methods In patients with LBBB, noninvasive epicardial mapping (ECG imaging) was performed during BVP and temporary HBP. Intrinsic activation was mapped in all subjects. Left ventricular activation times (LVAT) were measured and epicardial propagation mapping (EPM) was performed, to visualize epicardial wavefronts. Normal activation pattern and a normal LVAT range were determined from normal subjects. Results Forty‐five patients were included, 24 with LBBB and LV impairment, and 21 with normal 12‐lead ECG and LV function. In 87.5% of patients with LBBB, His‐CRT successfully shortened LVAT by ≥10 ms. In 33.3%, His‐CRT resulted in complete ventricular resynchronization, with activation times and patterns indistinguishable from normal subjects. EPM identified propagation discontinuity artifacts in 83% of patients with LBBB. This was the best predictor of whether successful resynchronization was achieved by HBP (logarithmic odds ratio, 2.19; 95% confidence interval, 0.07–4.31; p = .04). Conclusion Noninvasive electrocardiographic mapping appears to identify patients whose LBBB can be resynchronized by HBP. In contrast to BVP, His‐CRT may deliver the maximum potential ventricular resynchronization, returning activation times, and patterns to those seen in normal hearts.
Bibliography:Disclosures
Ahran Arnold, Daniel Keene, and Zachary Whinnett have received honoraria and research funding from Medtronic (Minneapolis, MN, USA). Angelo Auricchio is a consultant to Boston Scientific, Backbeat, Biosense Webster, Cairdac, Corvia, Microport CRM, EPD‐Philips, and Radcliffe Publisher. He received speaker fees from Boston Scientific, Medtronic, and Microport. He participates in clinical trials sponsored by Boston Scientific, Medtronic, and EPD‐Philips. He has intellectual properties with Boston Scientific, Biosense Webster, and Microport CRM. Other authors: No disclosures.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Disclosures: Ahran Arnold, Daniel Keene, and Zachary Whinnett have received honoraria and research funding from Medtronic (Minneapolis, MN, USA). Angelo Auricchio is a consultant to Boston Scientific, Backbeat, Biosense Webster, Cairdac, Corvia, Microport CRM, EPD‐Philips, and Radcliffe Publisher. He received speaker fees from Boston Scientific, Medtronic, and Microport. He participates in clinical trials sponsored by Boston Scientific, Medtronic, and EPD‐Philips. He has intellectual properties with Boston Scientific, Biosense Webster, and Microport CRM. Other authors: No disclosures.
ISSN:1045-3873
1540-8167
1540-8167
DOI:10.1111/jce.14845